Argenx stock sits at EUR 736.30 after a week of mixed trial news
Published on 10/10/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Argenx stock was EUR 736.30 in weekend trading on October 10, 2026.
- The company discontinued the UNITY Phase 3 study after an interim futility analysis.
- FB102 met its Phase 2 primary endpoint in celiac disease with p=0.0176.
On October 10, 2026, Argenx stock sits at EUR 736.30 in weekend trading at Lang & Schwarz, unchanged from the EUR 736.30 close on October 9, 2026. The company reported mixed clinical developments on October 8: it discontinued the UNITY Phase 3 study in Sjögren's disease, while its FB102 Phase 2 study in celiac disease met its primary endpoint. The announcements were issued by argenx SE through GlobeNewswire and Nasdaq.
The week in figures
Lang & Schwarz quoted Argenx at EUR 736.30 at 11:09 a.m. CEST on October 10, 2026. The bid was EUR 735.20 and the ask was EUR 737.40. The quote was unchanged against the EUR 736.30 close of October 9, 2026.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Argenx stock.
Chronology of the week
On October 8, 2026, argenx said an Independent Data Monitoring Committee recommended stopping the UNITY Phase 3 study for futility after an interim analysis. The company said the study could not meet its primary endpoint, which measured systemic disease activity at Week 48, according to GlobeNewswire.
Also on October 8, 2026, argenx reported that FB102 met the primary endpoint of its Phase 2 celiac disease study. The change in the ratio of villus height to crypt depth at day 78 versus placebo produced a p-value of 0.0176, according to Nasdaq.
Dates of the coming week
The next Xetra session is scheduled for October 12, 2026.
Market context: Market report AEX.
